Background
Phase III, double-blind, placebo-controlled RCT. 672 premenopausal women with HR+ HER2- advanced breast cancer. All received goserelin 3.6mg q28d for ovarian suppression. Endocrine backbone was physician's choice: NSAI (letrozole or anastrozole) or tamoxifen. First-line advanced disease; prior (neo)adjuvant endocrine therapy allowed if completed ≥12 months before enrollment.
Interventions and follow up
Arm A: Ribociclib 600mg days 1–21 of 28-day cycle + goserelin + NSAI or tamoxifen
Arm B: Placebo + goserelin + NSAI or tamoxifen
Primary endpoint: Progression-free survival (PFS)
mFollow up: 34.6 months (OS analysis)
Arm B: Placebo + goserelin + NSAI or tamoxifen
Primary endpoint: Progression-free survival (PFS)
mFollow up: 34.6 months (OS analysis)
Results
PFS: 23.8 vs 13.0mo, HR 0.553, 95% CI 0.441–0.694, P<.001
OS (interim): Not reached vs 40.9mo, HR 0.712, 95% CI 0.535–0.948, P=.02
OS at 42 months: 70.2% vs 60.7%
OS (interim): Not reached vs 40.9mo, HR 0.712, 95% CI 0.535–0.948, P=.02
OS at 42 months: 70.2% vs 60.7%
Adverse events
Hematologic (grade ≥3): Neutropenia 61.0% vs 4.0%
Cardiac: QTc prolongation grade ≥3 2.5%
Hepatic (grade ≥3): Elevated ALT/AST 13.3% vs 3.2%
Discontinuation due to AEs: 7.5% vs 2.1%
Cardiac: QTc prolongation grade ≥3 2.5%
Hepatic (grade ≥3): Elevated ALT/AST 13.3% vs 3.2%
Discontinuation due to AEs: 7.5% vs 2.1%
Conclusions
Ribociclib + OFS + endocrine therapy significantly improved PFS and OS in premenopausal HR+ HER2- advanced BC, representing the first CDK4/6 inhibitor trial to show an OS benefit in premenopausal patients. The 10% absolute OS improvement at 42 months is clinically substantial.
Key Limitations
Heterogeneous endocrine backbone (NSAI vs tamoxifen) and post-hoc subgroup analysis showing no OS benefit for the tamoxifen-containing arm create uncertainty about optimal backbone choice. Premenopausal women represent a historically understudied population in HR+ mBC trials — the NSAI subgroup result should guide backbone selection. QTc monitoring burden is added to the complexity of concurrent goserelin injections. OS analysis was interim with wide confidence intervals.
Clinical Context
MONALEESA-7 is the pivotal trial establishing CDK4/6 inhibitor + OFS + NSAI as standard first-line therapy for premenopausal HR+ HER2- mBC, with FDA and ESMO guideline endorsement. ESMO-MCBS score: 5. Notably, palbociclib and abemaciclib trials did not enroll premenopausal patients as a dedicated population with OS endpoints — ribociclib is the preferred CDK4/6 inhibitor in this setting for many clinicians.